FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to oncology and immunology, and can be used in treating an individual with a stable pathogenic infection or a tumour. That is ensured by administering a therapeutically effective amount of a programmed death (PD-1) peptide antagonist and a therapeutically effective amount of a pathogen or tumour antigen molecule (vaccine).
EFFECT: invention provides the synergetic action of the antigen and PD-1 antagonist (anti-PD-L1 antibody) combination by intensifying the T-cell immune response to the pathogen or tumour.
14 cl, 29 dwg, 5 tbl, 25 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS OF TREATING INFECTIONS AND TUMOURS | 2007 |
|
RU2478400C2 |
| METHODS AND COMPOSITIONS FOR TREATING PERSISTENT INFECTIONS | 2006 |
|
RU2596491C2 |
| METHODS AND COMPOSITIONS FOR TREATMENT OF PERSISTENT INFECTIONS | 2016 |
|
RU2746383C2 |
| METHOD AND COMPOSITIONS FOR TREATMENT OF PERSISTING INFECTIONS | 2006 |
|
RU2434641C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO PD-1 AXIS AND TIGIT INHIBITORS | 2014 |
|
RU2702108C2 |
| ANTIBODIES TO PD-L1 AND THEIR APPLICATION FOR T-CELLS FUNCTION STRENGTHENING | 2009 |
|
RU2636023C2 |
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS | 2014 |
|
RU2825390C2 |
| COMPOSITIONS AND METHODS OF IMMUNOTHERAPY | 2014 |
|
RU2680010C2 |
| STABLE COMPOSITIONS OF ANTIBODIES AGAINST PROGRAMMABLE DEATH RECEPTOR OF PD-1 PERSON AND RELATED TREATMENT | 2012 |
|
RU2633509C2 |
| YEAST-BASED IMMUNOTHERAPEUTIC COMPOSITIONS WITH BRACHYURY | 2012 |
|
RU2690180C2 |
